

**Abstract of the Disclosure**

Disease conditions which are dependent upon or moderated by angiogenesis are controlled by the use of a therapeutic material which interacts with cell surface galectins.

- 5 Particular therapeutic materials comprise a polymeric backbone having side chains terminating in a sugar dependent therefrom. Disclosed are specific therapeutic materials in which the polymeric backbone is based upon polygalacturonic acid, and the side chains terminate in arabinose or galactose.